These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Getting new drugs to market: how individuals could do this without leaving their desks. Collier J BMJ; 2006 Dec; 333(7582):1315-7. PubMed ID: 17185722 [No Abstract] [Full Text] [Related]
27. [Drug shortage--cause and prevention]. Madsen S; Claesson U; Wesenberg GR; Endresen M; Walter AB Tidsskr Nor Laegeforen; 2012 Oct; 132(19):2154-5. PubMed ID: 23076482 [No Abstract] [Full Text] [Related]
28. Value-based pricing of drugs in the UK. Webb DJ; Walker A Lancet; 2007 Apr; 369(9571):1415-1416. PubMed ID: 17467498 [No Abstract] [Full Text] [Related]
29. Andrew Witty: the acceptable face of big pharma? Interviewed by Rebecca Coombes. Witty A BMJ; 2013 Mar; 346():f1458. PubMed ID: 23468295 [No Abstract] [Full Text] [Related]
30. Interview with Dr Richard Barker, Director General of the Association of the British Pharmaceutical Industry. Barker R Future Med Chem; 2009 Jun; 1(3):421-6. PubMed ID: 21426122 [No Abstract] [Full Text] [Related]
31. An open source pharma roadmap. Balasegaram M; Kolb P; McKew J; Menon J; Olliaro P; Sablinski T; Thomas Z; Todd MH; Torreele E; Wilbanks J PLoS Med; 2017 Apr; 14(4):e1002276. PubMed ID: 28419094 [TBL] [Abstract][Full Text] [Related]
32. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke. Rawlins SM Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816 [No Abstract] [Full Text] [Related]
34. Pharmacy benefit managers and their obligations during serious prescription drug shortages. Teagarden JR; Epstein RS Clin Pharmacol Ther; 2013 Feb; 93(2):143-5. PubMed ID: 23337523 [TBL] [Abstract][Full Text] [Related]
35. The atopic dermatitis market. Pantazi E; Valenza G; Hess M; Hamad B Nat Rev Drug Discov; 2018 Apr; 17(4):237-238. PubMed ID: 29104285 [No Abstract] [Full Text] [Related]
36. Drug shortages in the United States: a critical evaluation of root causes and the need for action. Gupta DK; Huang SM Clin Pharmacol Ther; 2013 Feb; 93(2):133-5. PubMed ID: 23337520 [TBL] [Abstract][Full Text] [Related]
37. Value-based pricing: incentive for innovation or zero net benefit? Hughes DA Pharmacoeconomics; 2011 Sep; 29(9):731-5. PubMed ID: 21736392 [No Abstract] [Full Text] [Related]
38. How should we support pharmaceutical innovation? Grootendorst P Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991 [TBL] [Abstract][Full Text] [Related]
39. Moving pharma contracting into the era of accountability. Graf TR Am J Manag Care; 2017 Dec; 23(14 Spec No.):SP580-SP581. PubMed ID: 29297638 [No Abstract] [Full Text] [Related]
40. Take your pills, all your pills: drug makers nag patients to stay the course. Pollack A N Y Times Web; 2006 Mar; ():C1, C13. PubMed ID: 16649271 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]